Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

Axel Ducret(Roche (Switzerland)), Sebastian Spindeldreher, Hweixian Leong Penny(Amgen (United States)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Campbell Bunce(Babraham Institute), Sophie Tourdot(Pfizer (United States)), Noel Smith(Lonza (United Kingdom)), Mark A. Kroenke(Amgen (United States)), Kasper Lamberth(Novo Nordisk (Denmark)), Juliana Bessa(Roche (Switzerland)), Anaïs Manin(Babraham Institute), Grzegorz Terszowski(Novartis (Switzerland)), Timothy P. Hickling(Roche (Switzerland)), Chloé Ackaert(Exelis (United States))
mAbs
December 20, 2021
10.1080/19420862.2021.1993522
Cited by 57

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
|The AAPS Journal|2021|52
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
|The AAPS Journal|2023|41